( VANCOUVER and CARLSBAD CA May 31 20...)OncoGenex and Isis Announce OGX-011 Data to be Presented at ASCO,Health

VANCOUVER and CARLSBAD, CA, May 31, 2007 /PRNewswire-FirstCall/ - OncoGenex Technologies Inc. and Isis Pharmaceuticals, Inc. today announced that preliminary data from ongoing clinical studies of OGX-011 will be presented at the American Society of Clinical Oncology Annual Meeting (ASCO). Presentations will include data from a Phase II clinical study of OGX-011 in hormone refractory prostate cancer and data from a Phase I/II clinical study of OGX-011 in non-small cell lung cancer. ASCO takes place June 1-5, 2007 at McCormick Place in Chicago, Illinois.

    Information related to the presentations:


    Saturday, June 2, 2007


    Poster Presentation:   "A randomized Phase II study of OGX-011 in

                           combination with docetaxel and prednisone or

                           docetaxel and prednisone alone in patients with

                           metastatic hormone refractory prostate cancer

                           (HRPC)"

    Abstract Number:       5069

    Session:               Genitourinary (Prostate) Cancer, Poster Board

                           # 17

    Location:              E451a

    Session Time:          2:00 p.m. - 6:00 p.m.

    Presenter:             Kim N. Chi, M.D., FRCPC


    Poster Discussion:     "A randomized Phase II study of OGX-011 in

                           combination with docetaxel and prednisone or

                           docetaxel and prednisone alone in patients with

                           metastatic hormone refractory prostate cancer

                           (HRPC)"

    Abstract Number:       5069

    Session:               Genitourinary (Prostate) Cancer, Poster Board

                           # 17

    Location:              E Arie Crown Theater

    Session Date:          Saturday, June 2, 2007

    Session Time:          5:00 p.m. - 6:00 p.m.

    Presenter/Discussant:  Kim N. Chi, M.D./Celestia Higano, M.D.


    Sunday, June 3, 2007


    Poster Presentation:   "A
'"/>




Page: 1 2 3 4 
Related medicine technology :

1. OncoGenex Technologies Announces Phase II Data of OGX-011 in
Metastatic Breast Cancer at American Association for Cancer
Research 2007 Annual Meeting
2. Cell Therapeutics, Inc. Management to Discuss Todays Announcement
of Interim Pixantrone Study Results
3. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
4. Neose Announces Presentation of Positive Preclinical Data on
GlycoPEGylated Factor VIIa at the XXI Congress of the International
Society on Thrombosis and Haemostasis
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy
of BF-200 ALA In Actinic Keratosis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in
Randomized Phase IIB Aerolef Trial
7. BioSante Pharmaceuticals Announces New Findings for Potential Bird
Flu Vaccine
8. Portola Pharmaceuticals Announces Positive Data from a Phase II
Study of its Factor Xa Inhibitor at the XXI Congress of the
International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for
Oral Oleoyl-estrone
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient
Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of
Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study